A
Adrian R. Levy
Researcher at Dalhousie University
Publications - 213
Citations - 8464
Adrian R. Levy is an academic researcher from Dalhousie University. The author has contributed to research in topics: Population & Health care. The author has an hindex of 46, co-authored 211 publications receiving 7817 citations. Previous affiliations of Adrian R. Levy include Hastings Entertainment & Halifax.
Papers
More filters
Journal ArticleDOI
The case for expanding access to highly active antiretroviral therapy to curb the growth of the HIV epidemic
Julio S. G. Montaner,Robert S. Hogg,Evan Wood,Thomas Kerr,Mark W. Tyndall,Adrian R. Levy,P. Richard Harrigan +6 more
TL;DR: The potential role of HAART in HIV prevention and the resulting impact this would have on the cost-eff ectiveness of the treatment are examined.
Journal Article
Coding accuracy of administrative drug claims in the Ontario Drug Benefit database.
TL;DR: The reliability of coding of the Drug Identification Number, and the date, quantity and duration of the dispensation on claims sent to the ODB database is estimated to be low.
Journal ArticleDOI
Using and interpreting cost-effectiveness acceptability curves: an example using data from a trial of management strategies for atrial fibrillation.
TL;DR: There is very little uncertainty surrounding the decision to adopt rate-control compared to rhythm-control for patients with atrial fibrillation from a resource point of view, and the CEAC is useful to a decision maker faced with the choice of whether or not to adopt a technology.
Journal ArticleDOI
Use of high potency statins and rates of admission for acute kidney injury: multicenter, retrospective observational analysis of administrative databases
Colin R. Dormuth,Brenda R. Hemmelgarn,J. Michael Paterson,Matthew T. James,Gary F. Teare,Colette B Raymond,Jean-Philippe Lafrance,Adrian R. Levy,Amit X. Garg,Pierre Ernst +9 more
TL;DR: Use of high potency statin treatments is associated with an increased rate of diagnosis for acute kidney injury in hospital admissions compared with low potency statins, and the effect seems to be strongest in the first 120 days after initiation of statin treatment.
Journal ArticleDOI
Self-Reported Morisky Score for Identifying Nonadherence with Cardiovascular Medications
TL;DR: Using the Morisky scale to identify patients who have been nonadherent with chronic cardiovascular medications may be reasonable in some settings; however, the threshold score would have to be chosen based on a trade-off between sensitivity and PPV.